Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Cytotoxic Payloads for Antibody-Drug Conjugates

by David Thurston , Paul J. M. Jackson
Save 2% Save 2%
Current price ₹24,096.00
Original price ₹24,500.00
Original price ₹24,500.00
Original price ₹24,500.00
(-2%)
₹24,096.00
Current price ₹24,096.00

Imported Edition - Ships in 18-21 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Hardcover
  • ISBN13: 9781788010771
  • Binding: Hardcover
  • Subject: N/A
  • Publisher: Royal Society of Chemistry
  • Publisher Imprint: Royal Society of Chemistry
  • Publication Date:
  • Pages: 480
  • Original Price: USD 250.0
  • Language: English
  • Edition: 1
  • Item Weight: 930 grams
  • BISAC Subject(s): Oncology / General

Antibody-drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla(TM)), brentuximab vedotin (Adcetris(TM)), inotuzumab ozogamicin (Besponsa(TM)), gemtuzumab ozogamicin (Mylotarg(TM)) and moxetumomab pasudotox-tdfk (Lumoxiti(R))] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many.

The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity.

Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us